Mark Zuckerberg and wife Dr. Priscilla Chan recently announced a $3 billion initiative geared towards curing most of the world’s diseases called the Biohub. Through the Chan Zuckerberg Initiative, the couple managed to draw support from other billionaires and ordinary people alike in terms of funding and cooperation. Recently, the Facebook founder released a post detailing how a meeting with top scientists gave him hope that most, if not all of the world’s diseases will be gone by 2115.
The scientists in question are at the top of their fields with regards to dealing with illnesses and they come from multiple origins, including Stanford University and UC Berkeley. Heading the team is Dr. Cori Bargmann, who is a Rockefeller neuroscientist, Futurism reports.
Even with excellent brains behind the operation, the goal of eradicating even just a majority of the known diseases plaguing the world is a monumental undertaking. Much of the challenges has to do with research, which is a costly and time-consuming affair. The Biohub will take on a lot of the weight of the problems that usually prevent scientists from making swift progress, but even then, many would consider the 100-year timeline to be overly ambitious.
Zuckerberg and the team of scientists don’t seem to think so, however, and they point to the advancements that humanity has achieved in the last few decades in extending human lifespan. Global Futurist also notes how the initiative has already addressed one of the hurdles of getting to the point that they are aiming for; coordination.
There’s also the matter of the most recent innovations in medical and bioresearch to consider, which gives the lofty goals of a disease-free world a boost. There’s the new gene-editing tool called CRISPR, which is basically a starter kit for playing God. Then there’s the project called Cell Atlas, which aims to map all of the human body’s cells to address diseases that begin at the cellular level.


Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum
Quantum Systems Projects Revenue Surge as It Eyes IPO or Private Sale
Morgan Stanley Boosts Nvidia and Broadcom Targets as AI Demand Surges
Australia Releases New National AI Plan, Opts for Existing Laws to Manage Risks
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths
Banks Consider $38 Billion Funding Boost for Oracle, Vantage, and OpenAI Expansion
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment
Samsung Launches Galaxy Z TriFold to Elevate Its Position in the Foldable Smartphone Market
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 



